CTI BioPharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2022	2021	2020	2019	2018	2017 - 1994
Revenue	53.95	0	0	3.35	26.29	Upgrade
Revenue Growth (YoY)	-	-	-	-87.28%	4.55%	Upgrade
Cost of Revenue	3.51	0	0	0	0	Upgrade
Gross Profit	50.43	0	0	3.35	26.29	Upgrade
Selling, General & Admin	84.83	56.2	17.63	19.16	22.06	Upgrade
Research & Development	36.9	39.14	25.94	24.11	36.47	Upgrade
Other Operating Expenses	8.51	0	4.2	0.79	0.66	Upgrade
Operating Expenses	130.23	95.33	47.77	44.06	59.19	Upgrade
Operating Income	-79.8	-95.33	-47.77	-40.71	-32.9	Upgrade
Interest Expense / Income	13.14	2.42	0.83	1	1.21	Upgrade
Other Expense / Income	0.06	0.16	3.85	-1.69	-4.79	Upgrade
Pretax Income	-92.99	-97.91	-52.45	-40.02	-29.32	Upgrade
Net Income	-92.99	-97.91	-52.45	-40.02	-29.32	Upgrade
Preferred Dividends	0	0	0	0	0.08	Upgrade
Net Income Common	-92.99	-97.91	-52.45	-40.02	-29.4	Upgrade
Shares Outstanding (Basic)	115	90	71	58	56	Upgrade
Shares Outstanding (Diluted)	115	90	71	58	56	Upgrade
Shares Change	27.27%	26.67%	22.71%	3.39%	53.86%	Upgrade
EPS (Basic)	-0.81	-1.09	-0.74	-0.69	-0.52	Upgrade
EPS (Diluted)	-0.81	-1.09	-0.74	-0.69	-0.52	Upgrade
Free Cash Flow	-81.19	-84.89	-42.22	-27.82	-39.86	Upgrade
Free Cash Flow Per Share	-0.71	-0.94	-0.59	-0.48	-0.71	Upgrade
Gross Margin	93.49%	-	-	100.00%	100.00%	Upgrade
Operating Margin	-147.91%	-	-	-1217.07%	-125.14%	Upgrade
Profit Margin	-172.37%	-	-	-1196.41%	-111.83%	Upgrade
Free Cash Flow Margin	-150.50%	-	-	-831.75%	-151.61%	Upgrade
EBITDA	-77.9	-94.97	-51.09	-38.47	-27.52	Upgrade
EBITDA Margin	-144.40%	-	-	-1150.13%	-104.67%	Upgrade
Depreciation & Amortization	1.95	0.53	0.53	0.55	0.59	Upgrade
EBIT	-79.85	-95.49	-51.62	-39.02	-28.11	Upgrade
EBIT Margin	-148.02%	-	-	-1166.46%	-106.93%	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).